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ABSTRACT
The diffusely infiltrative nature of glioblastoma (GBM) makes them highly 
recurrent. IGF2 mRNA-binding protein 3 (IMP3), a GBM upregulated RNA binding 
protein, promotes glioma cell migration. An integrative bioinformatics analysis 
identified p65 (RELA), a subunit of NF-κB heterodimer as a target and an important 
mediator of IMP3 promoted glioma cell migration. IMP3 increased p65 protein levels 
without any change in p65 transcript levels, but promoted its polysome association. RIP-
PCR demonstrated the binding of IMP3 to p65 transcript. UV crosslinking experiments 
with in vitro transcribed RNA confirmed the specific and direct binding of IMP3 to 
sites on p65 3′UTR. Further, IMP3 induced luciferase activity from p65 3′UTR reporter 
carrying wild type sites but not mutated sites. Exogenous overexpression of p65 from 
a 3′UTR-less construct rescued the reduced migration of glioma cells in IMP3 silenced 
condition. In addition, IMP3 silencing inhibited glioma stem-like cell maintenance and 
migration. The exogenous overexpression of 3′UTR-less p65 significantly alleviated the 
inhibition of neurosphere formation observed in IMP3 silenced glioma stem-like cells. 
Further, we show that IMP3 is transcriptionally activated by NF-κB pathway indicating 
the presence of a positive feedback loop between IMP3 and p65. This study establishes 
p65 as a novel target of IMP3 in increasing glioma cell migration and underscores the 
significance of IMP3-p65 feedback loop for therapeutic targeting in GBM.
INTRODUCTION
Glioblastoma (GBM) is one of the leading causes 
of death caused due to brain tumors. Despite the technical 
advances in diagnostics and the present treatment modalities 
the median overall survival of the patients remains 14.6 
months [1, 2]. Malignant and heterogeneous nature of 
the GBM tumors contribute to the observed resistance 
and recurrence [3]. In the recent past, many authors have 
demonstrated the existence of a small population of glioma 
stem-like cells (GSCs) in the tumors which in multiple ways 
contribute to this heterogeneity and the belligerence of the 
disease [3–5] . They have been demonstrated to be resistant 
to the current treatment modalities and are ascertained to 
be the culprits for the high rates of GBM recurrence [4]. 
They have also been shown to have high migratory capacity 
[5]. Thus, the identification of molecules contributing to 
migratory potential of glioma cells and in GSC maintenance 
will help in adding lucrative potential targets for adjuvant 
therapies. Inhibition of such molecules will diminish the 
tumor load and resistance to existing therapies which may 
result in lower recurrence rate.
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Increasing evidence establishes the role of RNA 
binding proteins in regulating RNA splicing, stability, 
localization, modifications and translation [6, 7]. While, 
recent evidence associates derailed expression or activity 
of these RBPs with several genetic diseases including 
cancer, their cellular target repertoire, how they regulate 
the transcriptome and proteome and whether they can 
be used for therapeutic intervention warrants further 
investigation [8–11]. IMP3 is an example of an oncofetal 
RNA binding protein, which has been associated with 
various malignancies [12–16]. Few of the bonafide targets 
of the protein are emerging from the recent research [9]. 
In this study, we have identified p65 (RelA) as a mediator 
of IMP3 functions including migration of glioma cell 
lines and maintenance of GSCs. IMP3 binds to 3′UTR 
of p65 transcript and enhances its translation. p65 is a 
subunit of NF-κB transcription factor and this increase in 
translation of protein also resulted in a higher activity of 
the NF-κB pathway. Moreover, we demonstrate IMP3 to 
be a transcriptional target of p65. We have thus, delineated 
IMP3- NF-κB cascade by which IMP3 contributes in 
migration of glioma bulk and stem-like cells.
RESULTS
Identification of RELA/p65 as an IMP3 target in 
promoting glioma cell migration
We have previously demonstrated that high IMP3 
GBM tumors are highly migratory/ invasive as seen by the 
presence of IMP3 positive tumors cells in tumor infiltrating 
front, perivascular and subpial regions [17]. In this work, 
we set out to identify IMP3 targets that promote glioma 
cell migration. An integrated bioinformatics approach was 
used to identify IMP3 targets that encode transcription 
factors since they are global regulators (Figure 1A). 
Many RNA binding proteins regulate their targets at 
mRNA translation level, and few of the identified IMP3 
targets were also regulated at this level [17, 18]. We were 
particularly keen to identify transcription factors whose 
expression is regulated by IMP3 at the translation step. To 
begin with, we utilized the PAR-CLIP data containing a 
list of mRNAs with IMP3 binding sites and transcriptome 
data of IMP3 silenced condition in HEK293 cells from 
Hafner et al. [19]. Firstly, we selected transcripts that 
contained IMP3 binding sites and whose transcript levels 
are unaltered under IMP3 silenced conditions (n = 4132). 
Next, this list was compared with transcription factor (TF) 
data base [20] which identified a list of 404 TFs. We then 
superimposed the TCGA GBM transcriptome data and 
short listed 162 TFs with their transcript levels unaltered 
between high- and low-IMP3 GBM tumors. These TFs 
were arranged according to the number of IMP3 binding 
sites present in their mRNA (Supplementary Table 1). 
Among top 5 genes with 10 or more IMP3 binding sites, 
we chose p65 (RELA) for further studies since p65 is a 
member of NF-κB heterodimeric transcription factor 
complex [21]. NF-κB pathway has been extensively 
associated with aggressive phenotypes of GBM, especially 
migration, invasion, angiogenesis, chemo-resistance and 
GSC maintenance [22–24].
NF-κB primarily exists as a heterodimeric 
transcription factor consisting of p65 and p50 subunits 
[21]. To experimentally demonstrate that p65 is a target of 
IMP3, we measured the p65-dependent luciferase activity 
in glioma cells after modulating IMP3 levels. Exogenous 
overexpression of IMP3 in LN229 glioma cells increased 
luciferase activity in a concentration dependent manner, 
while knockdown of IMP3 in U87, T98G and U138 
cells led to a significant reduction in the activity from 
NF-κB dependent reporter (Figure 1B and 1C). Next, we 
assessed the role of p65 as a downstream effector of IMP3 
mediated migration. As expected, we observed a reduced 
migratory capacity of U138 cells upon IMP3 knockdown 
(Figure 1D and 1E; compare bar 1 with 2). Exogenous 
overexpression of p65 alleviated the diminished 
migration observed in IMP3 silenced U138 cells 
(Figure 1D and 1E; compare bar 4 with 2). Silencing of 
IMP3 and overexpression of p65 was confirmed using 
western blot (Figure 1F). Collectively, these results 
establish p65 as a target of IMP3 in mediating its pro-
migratory functions in glioma cells.
IMP3 activates NF-κB activity by promoting 
translation of p65 transcript
To dissect the mechanism behind the regulation of 
p65 and thereby NF-κB activity by IMP3, we checked the 
p65 transcript and protein levels in IMP3 overexpressed 
and knockdown conditions. p65 transcript levels in IMP3 
overexpressing LN229 cells or IMP3 silenced U87, 
A172, U138 and U343 cells was found to be unaltered 
(Figure 2A and 2B). Additionally, there was no significant 
difference in p65 transcript levels between low IMP3 and 
high IMP3 GBM samples from TCGA and GSE22866 
data sets (Supplementary Figure 1A and 1B). Moreover, 
we observed no significant correlation between p65 
protein and p65 transcript in our patient (GBM) cohort 
as assessed by immunohistochemical analysis (IHC) and 
qRT-PCR respectively (r = 0.2521, p = ns, Supplementary 
Figure 1C). We next analysed the effect of IMP3 on p65 
protein levels. While IMP3 overexpression resulted in 
many fold increase in p65 protein in LN229, U373 and 
U251 cells (Figure 2C), IMP3 silencing decreased the 
p65 protein levels in U87, A172, U138 and U343 cells 
(Figure 2D). Moreover, we found the protein levels 
of p65 and IMP3 were significantly correlating in our 
patient (GBM) cohort as assessed by IHC (r = 0.3648, 
p = 0.0175, Supplementary Figure 1D). Furthermore, 
this increased p65 protein is also functionally active, as 
evident by nuclear translocation of p65 protein in LN229 
and U251 cells with IMP3 overexpression (Supplementary 
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Figure 1E). Conversely, IMP3 knockdown led to 
reduced nuclear p65 staining in A172 and U343 cells 
(Supplementary Figure 1F). Thus, IMP3 increases the 
NF-κB activity by increasing the p65 protein levels, 
without any change in its transcript level. Further to 
determine the mechanism behind increased p65 protein 
levels in the presence of IMP3, we looked at the 
translation and protein stability of p65. In knockdown 
conditions of IMP3 in U138 cells, polysome analysis 
revealed a significant decrease in the p65 transcript level 
in polysome fraction and a concomitant increase of the 
transcript in the non-polysome fraction (Figure 2E). To 
check the effect of IMP3 levels on p65 protein stability, 
cycloheximide chase experiment was performed. The rate 
of degradation of p65 protein was seen to be similar in 
IMP3 overexpression conditions (AdIMP3) and control 
(AdGFP) LN229 cells, implying that IMP3 may not be 
playing a role in regulating the protein stability of p65 
(Figure 2F). Taken together, IMP3 increases the levels of 
p65 protein by increasing its mRNA translation.
IMP3 binds to 3′UTR of p65 RNA 
We next sought to investigate whether the increase 
in p65 translation is mediated via direct binding of IMP3 to 
the p65 transcript. The binding of IMP3 to p65 transcript 
Figure 1: IMP3 expression increases NF-κB activity. (A) Schematic representation of the strategy employed to find the transcription 
factor having putative IMP3 binding sites and unregulated at the level of RNA on IMP3 silencing (data provided in GSM545209 and 
http://www.mirz.unibas.ch/restricted/clipdata/RESULTS/CLIP_microArray/index.html) [19]. (B) NF-κB luciferase reporter activity in 
IMP3 overexpressing LN229 cells and in IMP3 silenced U87, T98G and U138 cells. For overexpression condition, NF-κB dependent 
reporter luciferase activity was co-transfected with IMP3 overexpression construct. Increasing concentrations of IMP3 expressing vector 
(1 μg and 2 μg) was used in the assay while keeping the reporter construct constant. Luciferase activity was measured after 48 h of 
transfection. For IMP3 silenced condition, the readings were taken after 48 h of reporter transfection, while 96 h after siRNA transfection. 
The activity obtained in vector control conditions was considered to be 1 and relative activities in increasing IMP3 conditions were plotted. 
(C) Western blots showing IMP3 levels upon exogenous IMP3 overexpression (LN229 cells) or silenced conditions (U87, T98G and U138 
cells). (D) Representative micrographs of migrated U138 cells in the mentioned conditions: siControl with control vector transfection, 
siControl with p65 overexpression vector transfection, siIMP3 with control vector transfection and siIMP3 with p65 overexpression vector 
transfection. (E) Quantitation of the number of migrated cells is represented as a bar graph. (F) Western blots confirming IMP3 silencing 
and p65 overexpression in U138 cells. For all experiments, a student t-test was carried to assign statistical difference in observations made 
in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
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was confirmed in the RNA immunoprecipitation assays, 
where the p65 transcripts were found to be enriched in 
IMP3 overexpressed fraction as compared to control 
fractions in LN229 cells (Figure 3A). Further analysis of 
p65 transcript sequence for the presence of IMP3 binding 
sites revealed that there are 10 potential binding sites, with 
four of them in 3′ UTR of the transcript (Supplementary 
Figure 2A). Since IMP3 binding sites are generally 
enriched in the 3′UTR of transcripts [19], and 3′UTR 
sites have been implicated in translational regulation, we 
investigated the importance of four sites present in the p65 
3′UTR. Based on the conservation of the sites across the 
species (Supplementary Figure 2B), the first three sites 
were taken up for studies.
The activity from a reporter construct with p65 
3′UTR having these three sites downstream to Renilla 
luciferase gene (Figure 3B) is induced in LN229 cells 
overexpressing IMP3 and is reduced in IMP3 silenced 
T98G cells (Figure 3C). UV crosslinking experiments 
using purified IMP3 protein, and radioactively labelled 
in vitro transcribed RNA corresponding to these three sites 
revealed that all the three sites are capable of binding to 
IMP3 (Figure 3D, left panel). This binding is specific as the 
cold RNA of the same site competed efficiently the binding 
by IMP3 (Figure 3E, right panel). Further, IMP3 failed to 
bind to a non-specific RNA (Supplementary Figure 2C). 
The importance of the predicted consensus sequence [19] 
in these sites for the specific binding by IMP3 was further 
confirmed by altering the important residues. Conversion 
of the first two residues CA to AC (Figure 3E) of the 
four nucleotide consensus 5′-CAUH-3′ [19] significantly 
abolished the binding by IMP3 (Figure 3F). To test the 
biological significance of IMP3 binding to p65 3′UTR, 
we tested the ability of IMP3 to activate a luciferase 
Figure 2: Mechanism of p65 expression regulation by IMP3. (A) Transcript levels of p65 and IMP3 in IMP3 overexpressing 
LN229 cells as assessed by qRT-PCR. Log2 ratio of transcript levels in AdIMP3 infected cells relative to AdGFP infected cells was plotted. 
(B) Transcript levels of p65 and IMP3 in IMP3 silenced conditions in glioma cell lines like U87, A172, U138 and U343. Measurement was 
done using qRT-PCR and the log2 ratio of transcript levels in siIMP3 transfected cells relative to siControl transfected cells was plotted. 
(C) Western blotting analysis of lysates from cell lines ectopically overexpressing IMP3 for the levels of IMP3, p65 and loading controls 
(Actin or PCNA). (D) Western blots showing levels of p65 and actin after IMP3 silencing. (E) Polysome analysis to measure the changes 
in p65 transcript translation in IMP3 knockdown condition was performed. p65 transcript levels were measured in non-polysome and 
polysome fraction in IMP3 and control knockdown condition by qRT-PCR. Log2 ratio of transcript levels in siIMP3 transfected cells 
relative to siControl transfected cells was plotted. (F) Western blot analysis followed by cycloheximide chase experiment. p65 levels 
were measured in these lysates. Quantitation of the remaining p65 expression (at 2, 4 and 6 hours) when compared to 0 hours in the two 
conditions is shown as the graph (right). For all experiments, a student t-test was carried to assign statistical difference in observations made 
in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
Oncotarget40473www.impactjournals.com/oncotarget
reporter construct carrying p65 3′UTR with the mutation 
in the IMP3 binding consensus as described earlier. To 
our surprise, site 1 mutation did not significantly affect 
the ability of IMP3 to activate the reporter activity, 
while both site 2 or 3 mutations abolished the ability of 
IMP3 to activate the reporter activity (Figure 3G). These 
observations underscore the importance of IMP3 binding 
to site 2 and site 3 over site 1 in physiological conditions. 
Thus, we conclude from these experiments that IMP3 
binds to the p65 3′UTR directly, and this binding may be 
important for its regulation on p65 expression.
A positive feedback loop between IMP3 and  
NF-κB pathway
We then investigated the possibility of IMP3 being 
transcriptionally activated by NF-κB pathway involving 
a positive feedback loop. To assess this possibility, we 
Figure 3: IMP3 binds to p65 transcript. (A) RNA immuno-precipitation (RIP) followed by qRT-PCR in LN229 cells transduced with 
AdGFP or AdIMP3 virus. RIP was performed 48 h post infection. p65 transcript levels were measured (qRT-PCR) in control antibody (IgG) 
or IMP3 antibody immunoprecipitated fractions from GFP virus and IMP3 virus infected cells and depicted. (B) Schematic representation of 
the luciferase construct used, where partial p65 3′UTR containing 3 putative IMP3 binding sites was cloned downstream to Renilla luciferase 
gene. (C) Construct carrying first three putative IMP3 binding sites in p65 3′UTR was transfected in ectopically IMP3 overexpressing 
cells (LN229) and IMP3 silenced cells (T98G). Luciferase readings were taken 48 h after reporter transfection and relative readings were 
plotted. (D) Phosphorimages after RNA-protein UV crosslinking experiments were performed. α 32P-labelled RNAs (~150 bases each) 
of corresponding sites were incubated in the absence or increasing concentrations of purified IMP3 protein. The radiolabel RNA-protein 
complexes were resolved on SDS-10% PAGE gels and phosphorimaging was performed (three left panels). α 32P-labelled RNA was also 
UV cross-linked to recombinant purified IMP3 protein, with 100, 200 and 400 fold molar excess of unlabelled same site RNA (cold RNA). 
Images after phosphorimaging for these experiments are also shown (three right panels). (E) Partial representation of the sites with four 
nucleotide consensus for IMP3 binding shown in bold letters. The first two mutated bases in the consensus are underlined in the mutated 
sequence. (F) Phosphorimages after RNA UV crosslinking experiments with wild type or the mutant RNA probes for the three sites. (G) 
Luciferase assay performed in IMP3 overexpressing LN229 cells transfected with wild-type or mutated 3′UTR plasmids. Each plasmid only 
had one site mutated as indicated, with the other two sites having wild type sequence. Luciferase readings were taken after 48 h of reporter 
plasmid transfection. Relative luciferase readings were calculated and depicted as bar graphs. For all experiments, a student t-test was carried 
to assign statistical difference in observations made in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as 
** and p < 0.001 is represented as ***.
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sub-cloned partial region of IMP3 promoter (−987 to 
+66) having four p65 binding sites upstream to Fire-fly 
Luciferase gene of pGL3-Basic vector to construct an 
IMP3 promoter-reporter construct (Figure 4A). Treatment 
of U87 and HCT116 cells with a pharmacological 
inhibitor to NF-κB pathway, BAY 11-7082 (an inhibitor 
of IKK complex activity) resulted in a dose dependent 
inhibition of luciferase activity from IMP3 promoter-
reporter construct (Figure 4B). BAY 11-7082 treatment 
also resulted in reduced IMP3 transcript (U343 and H1299 
cells) and protein levels (U87, U343 and H1299 cells) 
(Figure 4C and 4D). As expected, under these conditions, 
BAY 11-7082 treatment inhibited reporter activity from 
NFκB-dependent reporter (Supplementary Figure 3A). 
Further, activation of NF-κB pathway by TNF-α led to 
increase in IMP3 RNA and protein levels in LN229 and 
U251 cells (Figure 4E and 4F). TNF-α treatment resulted 
in the activation of reporter activity from NFκB-dependent 
reporter as anticipated (Supplementary Figure 3B). 
Additionally, a dominant negative form of IκB (IκBSR), 
an inhibitor of NF-κB pathway, decreased IMP3 transcript 
levels in U251 and U87 glioma cells (Figure 4G). We 
also found a significant positive correlation between p65 
protein (as determined by immunohistochemistry) and 
IMP3 transcript levels (as determined by qRT-PCR) in our 
cohort of GBM patient samples (r = 0.2976, p = 0.0304, 
Supplementary Figure 3C). We went ahead to check 
if p65 binds directly to IMP3 promoter by performing 
ChIP-qPCR. We found enhanced p65 occupancy on the 
IMP3 promoter region both in endogenous and TNF-α 
activated condition in U87 cells (Figure 4H). Analysis 
of IMP3 promoter region that was amplified for ChIP-
qPCR in UCSC genome browser [25] also showed an 
enrichment of activated histone marks (H3K27Ac marks) 
(Supplementary Figure 3D). To investigate whether 
IMP3 is itself able to increase its own transcription via 
p65, we checked for the IMP3 reporter activity in IMP3 
overexpression conditions. We see an increased IMP3 
promoter dependent luciferase reporter activity in IMP3 
overexpression condition in LN229 cells (Figure 4I) and 
this increase was abrogated by BAY 11-7082 treatment 
(Figure 4J). These results demonstrate the existence of a 
probable positive feedback loop between IMP3 and NF-
κB pathway in GBM.
IMP3-p65 cascade also regulates glioma stem-
like cells (GSC) maintenance and migration
Since GSCs show enhanced migratory property and 
IMP3 promotes migration of glioma cells, we were intrigued 
if there is any association between IMP3-p65 cascade and 
GSCs [17, 26–28]. We examined the transcript levels of 
1756 RNA binding proteins (RBPs) [29, 30] derived from 
GSE31262 microarray database, which provides transcript 
profile of five adult human neural stem cell lines (ahNSC) 
and nine glioblastoma stem cells lines (GSC) [31]. There 
were 73 RBPs upregulated and 73 RBPs downregulated 
in GSC in comparison to ahNSC (Figure 5A). Among the 
GSC specific upregulated RBPs, we found IMP3 to be 
the most upregulated (Fold change in GSC over ahNSC = 
92.94), suggesting that IMP3 may play an important role 
in GSC maintenance (Figure 5A; Supplementary Table 2). 
To confirm the association between IMP3 and GSCs, we 
carried out Gene Set Enrichment Analysis (GSEA) for the 
possible enrichment of gene expression profile of CD133+ 
(a marker for glioma stem-like cells) glioma cells [32], 
in IMP3 expressing glioma tumors. We found a positive 
enrichment of upregulated genes in CD133+ glioma cells 
(CD133+_up) in GBMs with high levels of IMP3 transcripts 
(IMP3 high) (Supplementary Figure 4A). In contrast, 
GBM tumors with low levels of IMP3 transcripts (IMP3 
low) had a positive enrichment of downregulated genes in 
CD133+ glioma cells (CD133+_down) (Supplementary 
Figure 4B). To experimentally validate the importance of 
IMP3 in GSC maintenance, we tested the effect of IMP3 
silencing on the ability of GSCs (SK1035 and MGG4) 
to grow as neurospheres. IMP3 silencing inhibited GSC 
neurosphere growth significantly both in terms of number 
and size (Figure 5B–5D). SK1035 and MGG4 GSCs have 
been described previously [33, 34] and were grown as 
neurospheres, which are known to enrich cells with stem-
like characteristics. IMP3 silencing also resulted in the 
downregulation of four glioma reprogramming transcription 
factors- OLIG2, POU3F2, SOX2 and SALL2 in GSCs 
(Figure 5E). These results were also reproduced in glioma 
cell lines, where a diminished neurosphere forming capacity 
was observed in A172, U87 and U251 cells transfected with 
siIMP3 (Supplementary Figure 4C and 4D). Next, we tested 
whether p65 is also a critical downstream mediator of IMP3 
in GSC maintenance using SK1035. The inhibitory effect 
of IMP3 depletion on neurosphere formation was tested 
in the presence of exogenously expressed p65 transcribed 
from a 3′UTR-less construct. IMP3 downregulation led to 
significant decrease in number of neurospheres as observed 
before (Figure 6A and 6B; compare bar 2 with 1). However, 
simultaneous exogenous overexpression of p65 rescued the 
neurosphere formation significantly (Figure 6A and 6B; 
compare bar 4 with 2). qRT-PCR confirmed the efficient 
silencing of IMP3 and p65 overexpression (Figure 6C). 
We also observed an increase in IMP3 transcript in p65 
overexpression condition establishing the regulation of 
IMP3 transcription by p65 in GSCs also (Figure 6C).The 
spheres formed upon p65 overexpression in IMP3 silenced 
condition indeed showed increased levels of SOX2, 
SALL2 and POU3F2 (Figure 6D). Next, we also checked 
if migration capacity of GSCs is regulated by IMP3. 
IMP3 knockdown led to decreased migration of SK1035 
GSCs (Figure 6E and 6F; compare bar 1 with 2). Further, 
we also observed an alleviation of reduction in migratory 
potential with p65 overexpression in IMP3 depleted cells 
(Figure 6E and 6F; compare bar 2 with 4). Taken together, 
these results underscore the importance of IMP3-p65 
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cascade in maintenance of glioma stem-like cells and their 
migratory capacity. 
DISCUSSION
IMP3 is an oncofetal RBP, implicated in migration, 
invasion, angiogenesis, cancer stem-like cell maintenance 
and is also associated with malignant and recurrent tumors 
[17, 35–41]. IMP3, being an RNA binding protein, has 
promiscuous binding and a plethora of target transcripts 
[18, 19]. From the multiple targets, we were interested 
to identify a global regulator, regulated by IMP3 at the 
level of translation, which may be playing a crucial role in 
migration of glioma cells. We focussed our efforts to IMP3 
Figure 4: IMP3 gene expression is regulated by NF-κB activity and both participate in a positive feedback loop. 
(A) Schematic representation of IMP3 promoter showing putative p65 binding sites revealed by bioinformatics analysis. The positions 
relative to Transcription Start Site (TSS) are indicated in the boxes. The putative consensus sequence of NF-κB binding in each of the sites 
is shown in red. (B) IMP3 promoter dependent luciferase activity of the cells transfected with IMP3 promoter reporter was measured after 
treatment with BAY 11-7082 at the indicated concentrations. Luciferase assays were performed 48 h after transfection and 12 h of inhibitor 
treatment. Luciferase readings were normalized to β-galactosidase readings present in the lysate. (C) Measurement of IMP3 transcript 
levels after treatment of U343 cells (left panel) and H1299 cells (right panel) with BAY 11-7082 (10 µM) at the indicated time points using 
qRT-PCR was performed. (D) Western blot analysis was performed to measure IMP3 protein levels in lysates of cells treated with BAY 11-
7082 (10 µM) for indicated time points. (E) Transcript levels of IMP3 in cells treated with TNF-α (10 ng/ml) for 4 h in LN229 and U251 
cells, as measured using qRT-PCR. (F) IMP3 protein levels in lysates made from cells treated with TNF-α (10 ng/ml) for the indicated 
time points. (G) Transcript levels of IMP3 in U251 and U87 cells after 48 h of IκB super repressor (IκBSR) transfection. Measurements of 
transcript levels were made using qRT-PCR. (H) ChIP was performed in untreated and TNF-α (10 ng/ml) treated U87 cells. qRT-PCR was 
performed to check the levels of region of IMP3 promoter amplified in p65 and control (IgG) immuno-precipitated chromatin. Relative 
enrichment of IMP3 promoter region in p65 pull-down over IgG pull-down conditions is shown in TNF-α treated and untreated cells. 
(I) Relative luciferase activity measurements of IMP3 promoter reporter in LN229 cells with ectopic overexpression of IMP3. All readings 
were recorded after 48 h of reporter transfection. (J) Relative luciferase activity measurements of IMP3 promoter reporter in LN229 cells 
ectopically expressing IMP3 treated or untreated with BAY 11-7082 (10 µM). All readings were recorded after 48 h of reporter transfection 
and 12 h of inhibitor treatment. For all experiments, a student t-test was carried to assign statistical difference in observations made in the 
conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
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mediated migration as our previously published results in 
GBM clearly reflect the importance of this molecule in 
this hallmark of cancer [17]. Our integrated bioinformatics 
approach identified p65, a transcription factor in NF-κB 
pathway to be a putative target of IMP3. NF-κB pathway 
activates a cascade of genes important during development 
and is also associated with aggressive and resistant tumors 
[42–44]. In addition, the level of NF-κB activation is 
directly proportional to tumor aggressiveness [45], and 
also implicated in cancer stem-like cell maintenance 
[24, 46–48]. In GBM, NF-κB pathway is constitutively 
active in a subset of tumors and represents a survival 
signal sustaining tumor growth [23]. It is also reported 
to play an important role in migration, invasion, GSC 
survival and chemoradiotherapy by its ability to activate 
various important oncogenes, including IL-6, IGFBP-2 
and c-myc, all of which are known regulators of migration 
capacity, glioma stem-like cells and are associated with 
tumor aggressiveness [49–51]. These reports motivated us 
to validate p65 as a target for IMP3 and as its downstream 
mediator in rendering migratory potential to the cells. 
Our findings in glioma cells with IMP3 overexpression 
and silencing unequivocally establish IMP3 as a positive 
modulator of NF-κB signalling by increasing the 
translation of p65 transcript. These results are in coherence 
with the observations made by Pei et al., where they have 
shown that IMP3 activates NF-κB pathway and contributes 
to migration of renal cell carcinoma cells [52]. Our p65 
rescue experiment in IMP3 depleted U138 glioma cells 
clearly reflects the importance of the molecule downstream 
Figure 5: IMP3 expression is associated with GSC maintenance. (A) Heat map showing significantly differentially expressed 
RNA binding proteins (73 up-regulated and 73 downregulated) between normal neural stem cells (n = 5) and glioma stem like cells 
(n = 8) from GSE31262. Log2 ratio values of expression are plotted ranging from −2 (green: downregulated) to +2 (red: upregulated). 
(b) Representative images showing decrease in sphere number and diameter after IMP3 silencing mediated by siRNA for SK1035 and 
MGG4 GSCs. (C) Quantitative representation of the relative decrease in sphere number after IMP3 depletion in GSCs using bar graph. 
The number of spheres in untreated condition was considered to be 1 and number of spheres in knockdown condition is plotted relative to 
it. (D) Number of spheres falling in different size categories (as per diameter in µm) plotted as bar graphs. Note that in IMP3 knockdown 
condition there is a general decrease in sphere diameter, but the number of spheres with bigger diameter is affected more severely in both 
SK1035 and MGG4 GSCs. (E) qRT-PCR analysis of transcript levels of known glioma stem-like cell markers upon IMP3 knockdown in 
SK1035 and MGG4 GSCs. Log2 ratio values of the transcript levels are plotted. For all experiments, a student t-test was carried to assign 
statistical difference in observations made in the conditions indicated. A p < 0.05 is represented with *p < 0.01 is represented as ** and 
p < 0.001 is represented as ***.
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to IMP3 in imparting migratory potential to these cells. 
We also show that IMP3 has a role to play in GSC 
maintenance and migration. GSCs are known for high 
migratory potential and therapy resistance [4, 27, 53] thus 
the association of IMP3 with GSCs makes it a lucrative 
target for therapy.
Another aspect investigated is the binding of IMP3 
to p65 3′UTR. Our results establish a specific binding 
of IMP3 to three sites on the p65 3′UTR. In luciferase 
assays with p65 3′UTR, we observed that mutation in 
site 1 did not significantly alter the enhanced activity in 
IMP3 overexpression conditions (as observed in wild type 
3′UTR construct). Conversely, mutation in either site 2 or 
site 3 significantly impaired the IMP3 mediated increase in 
luciferase activity. This signifies the importance of IMP3 
binding to these two sites (site 2 and site 3) in mediating 
its regulation in the cells. Though there may be various 
reasons behind this observation, one of the scenarios that 
we hypothesize is that IMP3 may be binding to site 2 and 
site 3 in a pseudodimeric configuration as proposed for 
IMP1 (a paralogue of IMP3) to its target [54]. Though the 
exact mechanism by which IMP3 promotes translation of 
target transcripts is not known, we hypothesize that it may 
involve recruitment of auxiliary proteins that may act as 
translation activators.
GBM tumors have high expression of p65 and IMP3 
proteins [17, 45]. Our results explicitly establish p65 as a 
target of IMP3 at the level of translation and also IMP3 
as a transcriptional target of p65. In light of the evidence 
provided, we conclude the existence of a positive feedback 
loop between IMP3 and p65. The presence of such a 
positive feedback loop in GBM tumors will further fuel 
Figure 6: IMP3 regulates GSC maintenance and migration via p65. (A) Representative images of SK1035 neurospheres formed 
in the four mentioned conditions: siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3 
with control vector transfection and siIMP3 with p65 overexpression vector transfection. (B) Quantification of neurospheres formed in the 
indicated conditions. (C, D) Transcript levels of IMP3, p65, SOX2, SALL2 and POU3F2 genes in SK1035 under the mentioned conditions: 
siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3 with control vector transfection 
and siIMP3 with p65 overexpression vector transfection. (E) Representative micrographs of migrated SK1035 GSCs in the mentioned 
conditions: siControl with control vector transfection, siControl with p65 overexpression vector transfection, siIMP3 with control vector 
transfection and siIMP3 with p65 overexpression vector transfection. (F) Quantitation of the number of migrated cells is represented as a 
bar graph. For all experiments, a student t-test was carried to assign statistical difference in observations made in the conditions indicated. 
A p < 0.05 is represented with *p < 0.01 is represented as ** and p < 0.001 is represented as ***.
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the belligerent state of the tumor. Thus, the disruption 
of this axis should bring down the aggressiveness of 
the tumor and its relapse. Taken together, we propose a 
model wherein IMP3 may enhance the translation of 
p65 thus contributing to activation of NF-kB pathway in 
GBM tumors. This may result in transcription of various 
oncogenes including cytokines and IMP3 itself. Thus our 
study establishes that the intricate regulation between 
IMP3 and NF-κB pathway is essential for migration of 
glioma cells (Figure 7).
The importance of this study relies on the fact 
that there are limitations in the utilization of NF-κB 
inhibitors for the management of various cancers. Pre-
clinical trials of NF-κB inhibitors have shown promising 
reduction in tumor burden, but serious concerns about 
side effects are still raised [55]. These observations 
thrust upon the importance of alternate strategies for 
NF-κB pathway inhibition. Molecules targeting IMP3 
could be considered for attenuating and disrupting 
NF-κB thus ensuring pronounced tumor specific inhibition 
with minimum side effects. Previously published report 
from our group demonstrated that IMP3 depletion results 
in enhanced sensitivity to chemotherapy in glioma cell 
lines [17]. Current study establishes that IMP3 is critical 
for migration of both differentiated and glioma stem-
like cells. Thus, IMP3 depletion may render even the 
GSCs, which have higher migratory potential and are 
refractory to the existing therapeutic modalities sensitive 
to chemotherapy. Further, it has been shown that peptides 
derived from IMP3 induce immune response of helper 
T cells and cytotoxic T lymphocytes resulting in better 
clinical response in esophageal cancer [56, 57]. Hence, 
IMP3 targeting may prove to be useful as an adjuvant 
therapy leading to targeting highly infiltrative cells thus 
improving the median survival, quality of life of patients 
and reducing the probability of recurrence in a patient.
MATERIALS AND METHODS
Culture of adherent cells and glioma stem-like cells
293T, U87 and HCT116 (Sigma); LN229, U138, 
U343, U251 (from Dr. Abhijit Guha’s laboratory), were 
grown in Dulbecco’s modified Eagle Medium (DMEM) 
Figure 7: Proposed model of regulation of p65 and IMP3 in GBM tumors. Low IMP3 expressing GBM tumors are relatively 
less invasive in nature. High IMP3 expressing GBM tumors will have high IMP3 protein resulting in enhanced translation of p65 transcript, 
and thus an increased expression of p65 protein is observed. The activated p65 translocates to the nucleus and induces the expression of 
NF-κB target genes including several cytokines and oncogenes. IMP3 also acts as another transcriptional target of p65 and the levels of 
both molecules are regulated in a positive feedback loop (depicted by long red arrow). This contributes in enhanced glioma cell migration 
and GSC maintenance in high IMP3 expressing GBM tumors. 
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supplemented with 10% Foetal Bovine Serum (10% FBS), 
penicillin (Sigma, U.S.A.), gentamicin (Sigma, U.S.A.) 
and streptomycin (Sigma, U.S.A.) at 37°C in a humidified 
atmosphere with 5% CO2. Primary tumor GSCs were kindly 
given by Dr. Santosh Kesari (University of California, 
San Diego) and Dr. Wakimoto H. (Massachusetts General 
Hospital, Boston). They were cultured in Neurobasal 
medium (Invitrogen, U.S.A.) supplemented with 3 mmol/L 
L-Glutamine (Invitrogen, U.S.A.), basic fibroblast growth 
factor (bFGF; 20 ng/ml, Promega), epidermal growth factor 
(EGF; 20 ng/ml; Promega), 1X B27 supplement (Invitrogen, 
U.S.A.), 0.5 × N-2 (Invitrogen, U.S.A.), 2 μg/mL Heparin 
(Sigma, U.S.A.), penicillin, gentamicin and streptomycin 
in ultra-low attachment plates (Corning, U.S.A.). SK1035 
neurospheres were passaged by mechanical dissociation after 
days 8–10, while chemical dissociation kit (Catalog# 05707, 
STEMCELL technologies, U.S.A.) was used for dissociation 
of MGG4. Fresh medium was supplemented every 2–3 days.
Human tumor samples
Source of tumor samples are GBM patients operated 
at National Institute of Mental Health and Neurosciences 
(NIMHANS) and Sri Sathya Sai Institute of Higher 
Medical Sciences (SSSIHMS), Bangalore, India. Tissues 
were bisected and one portion was used for placed in 
RNA later (Ambion Inc., USA), stored at −70°C and used 
for RNA isolation, while the other half was fixed in 10% 
buffered neutral formalin, processed for paraffin sections 
and was used for immunohistochemistry (IHC). The study 
was approved by the ethics committee of NIMHANS 
and SSSIHMS (the two clinical centres) and the consent 
of the patients was obtained as per the Institute Ethical 
Committee guidelines and approval. For assessing the 
transcript levels of various genes (IMP3 and RELA) in 
tumor samples we had used forty six GBM samples.
Plasmids and other reagents 
IMP3 overexpression construct used has been 
described earlier [17]. IMP3 promoter reporter was 
procured from Switch Gear genomics (S717055) and sub-
cloned into pGL3 Basic vector (Promega, U.S.A.). NF-κB 
dependent luciferase reporter vector was a kind gift from 
Dr. Balaji, IISc, India. IκB super-repressor (IκBSR) was 
kindly provided by Dr. Inder Verma. pAG23 RELA 3ʹUTR 
was a gift from David Bartel (Addgene plasmid # 14505).
Control siRNA pool (Catalog # D-001810-10-50) 
and siRNA pool used against IMP3 (GenbankTM accession 
number NM_006547; Catalog # L-003976-00-0050) were 
purchased from GE HealthCare Dharmacon Inc (On-
TARGET plus Human siRNA SMART pool). These siRNA 
against IMP3 contains a pool of 4 siRNAs. The details of 
these are given in previously published literature [17]. GFP 
Adenovirus and IMP3 adenovirus used were described 
earlier in previously published literature [17]. BAY 
11-7082 (Calbiochem, U.S.A.) and TNF-α (Cell Signaling 
Technology, U.S.A.) were also used in this study. 
RNA isolation and real-time quantitative RT-PCR 
analysis
Total RNA was isolated using TRI reagent (Sigma, 
U.S.A.) and 2 µg of RNA was reverse transcribed using 
the High capacity cDNA reverse transcription kit (Life 
technologies, USA) according to the manufacturer’s 
protocol. qRT-PCR was performed using the ABI PRISM 
7900 HT Sequence Detection System (Life technologies, 
USA). Expression of the genes of interest was analyzed 
and normalized to 18S rRNA, ATP5G1, AGPAT or 
RPL35a as internal control genes following the ΔΔCt 
method [58]. The primer sequences used for p65 and IMP3 
are p65 (forward): GAAGAAGAGTCCTTTCAGCG, 
p65 (reverse): GGGAGGACGTAAAGGGATAG, IMP3 
(forward): CACCTCTGCGGCTTGTAAGTC, IMP3 
(reverse): CAGCGTCAATTCCTGCAATGG, POU3F2 
(forward): TGACGATCTCCACGCAGTAG, POU3F2 
(reverse): GGCAGAAAGCTGTCCAAGT, SOX2 
(forward): AACCCCAAGATGCACAACTC, SOX2 
(reverse): GCTTAGCCTCGTCGATGAAC, SALL2 
(forward): TAATCTCGGACTGCGAAGG, SALL2 
(reverse): TAGAACATGCGTTCTGGTGG, OLIG2 
(forward): CCAGAGCCCGATGACCTTTT, OLIG2 
(reverse): AGGACGACTTGAAGCCACTG
Western blotting
Equal amount of lysates (quantified using Bradford 
reagent) were resolved on SDS-PAGE gels, transferred 
on PVDF membrane and probed with antibodies against 
IMP3 (Catalog # HPA002037, Sigma, U.S.A.), actin 
(Catalog # A3854, Sigma, U.S.A.), PCNA (Catalog # 
NA-03, Calbiochem, U.S.A.) and p65 (Catalog # 3034S, 
Cell Signaling Technology, U.S.A.). For cycloheximide 
chase experiment, cylcoheximide (50 µg/ml) (Sigma, 
U.S.A.) was added to the cells and the cells were harvested 
at the indicated time points. The lysates were made and the 
western blotting was performed. The blots were probed for 
p65 and the loading control. 
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde, 
washed with Tris-buffered saline, and incubated with 
anti-p65 (Catalog # 8242, Cell Signaling Technology, 
U.S.A.). Primary antibodies were incubated for 16 h at 
4°C followed by detection with Alexa 488 anti-rabbit 
(Invitrogen). Nuclei were stained with DAPI (Sigma) and 
slides were mounted using anti-fade (Invitrogen). Images 
were taken with a confocal microscope (Leica, U.S.A.).
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Luciferase reporter assay
IMP3 promoter region was purchased from Switch 
gear genomics and the promoter region was sub-cloned in 
pGL3-Basic vector. NF-κB reporter luciferase construct 
was a kind gift from Dr. K.N. Balaji (IISc., Bangalore 
India). Luciferase assays were performed using reporter 
lysis buffer RLB (catalog # E3971, Promega, U.S.A.) 
and Luciferase Assay reagent (LAR, catalog # E1500, 
Promega, U.S.A.) as per manufacturer’s instructions. 
Briefly, plasmids were transfected in the cells plated in 
12 well plates using Lipofectamine 2000 (a total of 
2–4 μg in each well). Cells were harvested after 48 h of 
transfection and lysates were made. Luciferase readings 
were recorded using luminometer. β-galactosidase assays 
or Renilla luciferase readings were performed to normalize 
the transfection differences. These assays were carried in 
duplicates. 
For 3′UTR luciferase assays, the plasmid was 
obtained for Addgene. The wild type or mutated 3′UTR 
plasmids (containing Renilla luciferase) were co-
transfected with pCMV-luc (having firefly luciferase 
gene) and the luciferase assays were performed using dual 
luciferase assay kit (Catalog # E1910, Promega, U.S.A.). 
Transfection of GSCs, neurosphere assay and 
sphere diameter measurement
GSCs transfections were carried out in single cell 
suspension state for both siRNA and plasmids. After 
48 h of transfection, the aggregates formed were 
dissociated into single cells, counted and equal numbers 
of cells were plated at a density of 4 cells/µl in 24-well or 
6-well plate. Number of spheres was counted after 7 days of 
plating. Again, fresh medium was added to the wells every 
2–3 days. Sphere diameter measurements were done with 
ImageJ software. Number of spheres above the median 
diameter were calculated and plotted for total number of 
spheres. These assays were performed in duplicates.
Migration of glioma cells and GSCs
U138 glioma cells and SK1035 GSCs were 
transfected with control siRNA or siRNA against IMP3. 
After 36 h of transfection, cells were plated for p65 
overexpression transfection (5 μg in a 35 mm). After 36 
h of p65 transfection, cells were made into single cell 
suspension and 25,000 cells were plated for migration in 
a Corning® BioCoat™ Control Inserts with 8.0 µm PET 
Membrane (Catalog # 354578, Corning, U.S.A.). Upper 
chamber contained incomplete medium required for the 
growth of respective cell lines, while the lower chamber 
contained medium with 20% serum. Migration of cells 
was observed after 8 h of incubation in 37°C incubator. 
Cells from the upper side of the chamber were gently 
removed, while those in the lower side were fixed using 
chilled methanol (30 min) and stained with 0.1% crystal 
violet (30 min). Representative images were taken under 
light microscope and migrated cells were counted. The 
assay was performed in duplicates.
IMP3 protein purification 
pET42a-IMP3 was obtained as a gift from Jan 
Christiansen. Untagged protein was purified as mentioned 
before without any modifications [59].
In vitro RNA transcription and site directed 
mutagenesis
DNA fragments were obtained by amplifying 
the site 1, site 2 and site 3 from the pAG23 RELA 3′ 
UTR plasmid. Amplification of region from each site 
was done using forward primer having T7 promoter 
which were then used as template in vitro transcription. 
These transcripts were also labelled using α-32P 
during the reaction. The transcription reactions were 
carried out using T7 RNA polymerase (Promega, 
U.S.A.) according to the manufacturer’s instructions. 
Primers used for amplification for templates for 
in vitro transcription are site 1 (forward): TAATACG 
ACTCACTATAGGGAGATTTTATTGTCAGTATCTG, 
site 1 (reverse): GTTCCCTACAGAGAAGGGAGCT 
GACC, site 2 (forward): TAATACGACTCACTATA 
GGGAGAGGAGGTAAGGCCTTTGAGCC, site 2 
(reverse): CGCTGGTGTTAGGCACAGGGACAATGCC, 
site 3 (forward): TAATACGACTCACTATAGGGAGAG 
TGCCTAACACCAGCG, site 3 (reverse): GGAACTGAC 
CAGACCAAACCCCTTCTGG.
Mutation of IMP3 binding consensus in three 
sites of p65 3′UTR was performed by site directed 
mutagenesis using the QuickChange® XL Site-directed 
Mutagenesis Kit (Catalog # 200516) from Stratagene 
(Agilent Technologies, U.S.A.) following manufacturer’s 
instructions. The primers used for mutagenesis are - site 
1: GGAGGTGCTTAAGCAGAAGACTTAACTTCTCT 
GGAAAGGG, site 2: GTCTTCCATCATGGATTACTTA 
CAGCTTAATCAAAATAACGCC and site 3: TCT 
TTCCTTGCTCAACACTGGCTGAAGGAAACCAG. 
The template used was pAG23 RELA 3′UTR plasmid.
UV crosslinking of RNA with IMP3 protein
For UV crosslinking, α-32P UTP-labelled radioactive 
probes of the IMP3 binding sites in p65 3′UTR were 
in vitro transcribed. The DNA substrates used were 
LN229 cDNA, wild type or mutant RELA 3′UTR plasmid 
(Addgene). The protocol for UV crosslinking was 
followed as described earlier [60]. Briefly, α-32P UTP-
labelled RNA probes were incubated with the purified 
IMP3 protein (1 × = 2.35 pmol) in RNA binding buffer 
at 30°C for RNA-protein complex formation. Protein was 
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quantified using Bradford reagent in spectrophotometer. 
RNA and protein were subjected to UV crosslinking for 
20 minutes. This was followed by RNase A treatment 
(30 µg) at 37°C for 30 min to remove the unbound RNA. 
Protein-RNA complexes were resolved on SDS-10% 
PAGE. The gel was subjected to phosphorimaging and 
analyzed.
RNA immunoprecipitation (RIP)
Protocol was followed as described earlier [17]. 
Briefly, LN229 cells were infected with AdGFP or 
AdIMP3. After 48 h, cells were lysed in lysis buffer 
containing 100 mM KCl, 5 mM MgCl2, 10 mM HEPES 
pH = 7.0, 0.05% Nonidet P-40, 1 mM DTT, 100 U/mL 
RNase inhibitor, and 1X protease inhibitor cocktail. The 
lysates were spun at 13000 rpm for 30 minutes and protein 
concentration of supernatants was quantified. Supernatants 
from each condition (containing equal protein 
concentration) were incubated with IgG control antibody 
and anti-IMP3 antibody (AntiIMP3, N19, sc-47893, Santa 
Cruz) at 4°C overnight. BSA blocked Protein-G sepharose 
beads were added to immobilize the immunocomplexes 
formed. Washes with lysis buffer containing 10% 
NP-40 were given, which was followed by Proteinase K 
and DNase treatment. Finally, RNA was extracted using 
TRI reagent and precipitated using alcohol. cDNA was 
made using this RNA as template and used for qRT-PCR 
for the assessment of the p65 transcript (Primer sequences 
forward: GAAGAAGAGTCCTTTCAGCG, reverse: 
GGGAGGACGTAAAGGGATAG).
Chromatin immunoprecipitation (ChIP) assays
ChIP procedure followed is detailed in our earlier 
publication [23]. Briefly, U87 cells were untreated or 
treated with PBS or TNF-α were processed for ChIP 
assay. Firstly, to crosslink protein and DNA, cells were 
incubated with 1% formaldehyde for 10 minutes at 25°C. 
2.5 M glycine for 5 minutes at room temperature (25°C) 
was used to stop the crosslinking. Cells were washed 
with cold PBS, lysed using lysis buffer. Chromatin was 
sonicated (10 sec pulse 10 times, duty cycle 80, power 
18) to generate sheared fragments falling in the range of 
100bp to 1000bp. Crosslinked chromatin complex was 
pre-cleared with protein G sepharose beads. p65 antibody 
(10 μl; Catalog # 8242, Cell Signaling Technology, 
U.S.A.) or control mouse antibody (IgG) was used to 
immunoprecipitate the p65 bound DNA fragments. 
Antibody-p65-DNA complex was captured using protein 
G sepharose beads and washed. Protein-DNA complexes 
reverse crosslinked and DNA was eluted. To assay the 
p65 binding to IMP3 promoter, IMP3 promoter specific 
primers (forward, 5′- GGCTGCGGTTCCTTTAG-3′ 
and reverse, 5′- TAGGAGGAGGCGGGATTAGC -3′; 
amplicon size-115 bp) were used and qRT-PCR was done 
as described previously. Fold enrichment method was used 
to calculate the p65 binding to IMP3 promoter in different 
conditions.
Bioinformatics analysis
 PAR-CLIP data (GSM545209) and knockdown data 
for IMP3 [19] was downloaded from starBase v2.0 (http://
starbase.sysu.edu.cn/) [61] and http://www.mirz.unibas.
ch/restricted/clipdata/RESULTS/CLIP_microArray/
index.html respectively and analysed. In this analysis, 
genes having non-significant p-value (p-value > 0.05) 
for differential expression mock and IMP3 knockdown 
conditions and the genes having difference in Log2 
ratios in range of – 0.57 and 0.57 between these two 
conditions were taken as unregulated. Stringent cut off 
(T2C frequency > 0.5) for IMP3 binding to transcripts 
was used to shortlist genes. Moreover, the list of animal 
transcription factors was retrieved from AnimalTFDB 
[20]. Transcription factor list was arranged using the 
number of binding sites present in the transcript as 
reflected by T2C positions.
Differential expression of RNA binding proteins 
in NSC versus GSC was performed using GSE31262. 
Publically available microarray datasets like TCGA 
(https://tcga-data.nci.nih.gov) and GSE22866 [62] were 
used for plotting RNA expression of p65 in IMP3 high 
and low tumors. The datasets, were stratified into high and 
low IMP3 expressing tumors with almost equal number of 
GBM tumor samples: TCGA (high IMP3: n = 147; low 
IMP3: n =176) and GSE22866 (high IMP3: n = 16; low 
IMP3: n = 12).
MEGA 6 was used to represent the conservation of 
consensus sequence in IMP3 binding sites at p65 3′UTR. 
Prediction of p65 binding sites on IMP3 promoter was 
performed using Physbinder (http://bioit.dmbr.ugent.be/
physbinder/index.php) [63].
A computational approach of GSEA [64] was 
undertaken to evaluate the TCGA Agilent microarray 
data for the enrichment of genes up regulated and down 
regulated in GSCs in IMP3 high and low defined tumor 
groups respectively. Defined gene sets (Yan_UP_IN_
CD133_GBM [65], Yan_DOWN_IN_CD133_GBM 
[65], BEIER_GLIOMA_STEM_CELL_UP [66] and 
BEIER_GLIOMA_STEM_CELL_DOWN [66]) from 
the Molecular Signature Database version 3.0 (MSigDB) 
were used to evaluate whether statistically significant 
differences existed between the enrichment of gene sets 
in the two groups of High and Low IMP3 tumors. We 
acknowledge our use of the gene set enrichment analysis, 
GSEA software, and Molecular Signature Database 
(MSigDB) [64] (http://www.broad.mit.edu/gsea/). 
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Polysome analysis
The analysis was performed on U138 glioma cells 
transfected with control siRNA or siRNA against IMP3. 
Protocol was described earlier [17].
Histology and immunohistochemistry
GBM tumor sections were processed and stained 
for p65, IMP3 and Sox-2 expression. 4mm sections were 
collected on silane coated glass slides. Antigen retrieval 
was performed by heat treatment in Tris-EDTA buffer 
(10 mM Tris Base, 1 mM EDTA solution, 0.05% Tween 
20, pH 9.0) at 850 W for 5 mins, 600 W for 10 mins and 
450 W for 5 mins respectively. After initial processing, 
the sections were incubated with the mentioned 
antibodies. Incubation with secondary antibody (MACH-
1 Universal HRP-Polymer Detection kit) was followed. 
3,3′-Diaminobenzidine (Sigma-Aldrich) was used as 
chromogenic substrate. A semiquantitative grading scale 
was used and the intensity of the immunoreactivity was 
decided as follows: zero (0) if the staining was absent, 1+ 
for moderate staining and 2+ if it was strong. For IHC, 
antibodies used were p65 (Catalog # 8242, Cell Signaling 
Technology, U.S.A.), IMP3 (Catalog # ab109521, U.S.A.) 
and SOX2 (Catalog # 3579, Cell Signaling Technology, 
U.S.A.).
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